UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2020
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 1-15525 | | 36-4316614 |
(State or other jurisdiction of incorporation) | | (Commission file number) | | (IRS Employer Identification No.) |
| | |
One Edwards Way, Irvine, California | | 92614 |
(Address of principal executive offices) | | (Zip Code) |
(949) 250-2500
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $1.00 per share | | EW | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
On May 7, 2020, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”), at which stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 350 million shares to 1.05 billion shares for the purpose of effecting a three-for-one forward split. The Amendment became effective immediately upon filing with the Secretary of State of the State of Delaware on May 7, 2020. The Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 5.07. | Submission of Matters to a Vote of Security Holders |
On May 7, 2020, the Company held its Annual Meeting. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting are as follows:
| (i) | Proposal 1: All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below: |
| | | | | | | | | | | | | | | | |
Nominee | | For | | | Against | | | Abstain | | | Broker Non-Votes | |
Michael A. Mussallem | | | 157,481,237 | | | | 8,474,454 | | | | 1,249,682 | | | | 12,905,840 | |
Kieran T. Gallahue | | | 147,398,516 | | | | 19,608,737 | | | | 198,120 | | | | 12,905,840 | |
Leslie S. Heisz | | | 166,136,448 | | | | 869,369 | | | | 199,556 | | | | 12,905,840 | |
William J. Link, Ph.D. | | | 157,861,919 | | | | 8,151,087 | | | | 1,192,367 | | | | 12,905,840 | |
Steven R. Loranger | | | 164,712,949 | | | | 2,285,664 | | | | 206,760 | | | | 12,905,840 | |
Martha H. Marsh | | | 164,712,482 | | | | 2,299,683 | | | | 193,208 | | | | 12,905,840 | |
Ramona Sequeira | | | 166,609,905 | | | | 379,443 | | | | 216,025 | | | | 12,905,840 | |
Nicholas J. Valeriani | | | 164,696,291 | | | | 2,281,116 | | | | 227,966 | | | | 12,905,840 | |
| (ii) | Proposal 2: The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below: |
| | | | | | |
For | | Against | | Abstain | | Broker Non-Votes |
156,231,572 | | 10,652,305 | | 321,496 | | 12,905,840 |
| (iii) | Proposal 3: The 2020 Nonemployee Directors Stock Incentive Program was approved as set forth below: |
| | | | | | |
For | | Against | | Abstain | | Broker Non-Votes |
158,980,270 | | 7,898,492 | | 326,611 | | 12,905,840 |
| (iv) | Proposal 4: The amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock for the purpose of effecting a three-for-one stock split was approved as set forth below: |
| | | | |
For | | Against | | Abstain |
178,250,404 | | 1,712,375 | | 148,434 |
| (v) | Proposal 5: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 was approved as set forth below: |
| | | | |
For | | Against | | Abstain |
170,659,116 | | 9,217,670 | | 234,427 |
| (vi) | Proposal 6: The advisory stockholder proposal regarding action by written consent was not approved as set forth below: |
| | | | | | |
For | | Against | | Abstain | | Broker Non-Votes |
29,599,433 | | 136,875,003 | | 730,937 | | 12,905,840 |
| Item 7.01. | Regulation FD Disclosure |
On May 7, 2020, the Company issued a press release announcing the retirement of Wesley von Schack from the Board of Directors, the appointment of Martha Marsh as the new Lead Independent Director, the election of Ramona Sequeira to the Board at the Annual Meeting and a three-for-one stock split of the outstanding shares of the Company’s common stock. A copy of the press release is attached as Exhibit 99.1, and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 8, 2020
| | |
EDWARDS LIFESCIENCES CORPORATION |
| | | |
By: | | /s/ Linda J. Park |
| | Linda J. Park |
| | Vice President, Associate General Counsel, and Secretary |
